Reaction

Erythema Nodosum reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 3,456 reports · 91 co-occurring drugs

As of the last recalculation, Erythema Nodosum appears in 3,456 FAERS reports alongside 91 co-occurring drug terms. The strongest observed disproportionality signal is INFLIXIMAB-DYYB (PRR 75.6).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Infliximab-Dyyb	332	75.6	76.4
Dabrafenib	81	23.7	23.8
Trametinib	72	18.3	18.4
Azathioprine	239	17.5	17.5
Infliximab	499	15.9	16.0
Terbinafine Hydrochloride	22	15.0	15.0
Vemurafenib	28	14.1	14.2
Adalimumab-Fkjp	95	12.7	12.7
Adalimumab-Adaz	106	12.4	12.5
Adalimumab-Aaty	93	12.1	12.2
Mesalamine	108	11.9	11.9
Hydrocortisone Sodium Succinate	18	11.6	11.6
Vedolizumab	155	11.3	11.3
Dimenhydrinate	18	10.2	10.2
Mercaptopurine	29	10.1	10.2
Anti-Itch	107	9.9	9.9
Anti-Pruritic	107	9.9	9.9
Antipruritic (Anti-Itch)	107	9.9	9.9
Cool Relief Gel With Aloe	107	9.9	9.9
Drs. Hydrocortisone	107	9.9	9.9
Hydrocortisone Continuous Spray	107	9.9	9.9
Hydrocortisone Spray	107	9.9	9.9
Anti-Itch Cream	107	9.9	9.9
Hydrocortisone Lotion	107	9.9	9.9
Hydrocortisone Cream 1%	107	9.9	9.9
Hydrocortisone Cream 1/2%	107	9.9	9.9
Hydrocortisone 1%	107	9.9	9.9
Hydrocortisone Cream	107	9.8	9.9
Anti-Thymocyte Globulin (Rabbit)	13	9.7	9.8
Hydrocortisone Acetate	114	9.7	9.7
Cholestyramine	19	9.5	9.5
Hydrocortisone	124	8.6	8.7
Diphenhydramine	76	7.4	7.4
Encorafenib	11	6.7	6.7
Isotretinoin	54	6.7	6.7
Colchicine	28	6.4	6.5
Metronidazole	65	6.2	6.2
Minocycline	12	6.2	6.2
Budesonide	56	5.8	5.8
Iron Sucrose	9	5.7	5.7
Azacitidine For	17	5.7	5.7
Mometasone	17	5.6	5.6
Ceftriaxone Sodium	35	5.5	5.5
Bosutinib	8	5.4	5.4
Azacitidine	26	5.3	5.3
Felodipine Extended-Release Tablets	10	5.3	5.3
Felodipine	10	5.3	5.3
Ceftriaxone	28	5.2	5.2
Loperamide Hcl	11	5.2	5.2
Metronidazole Topical	37	4.7	4.7
Atovaquone	6	4.5	4.5
Sirolimus	10	4.5	4.5
Methotrexate	291	4.5	4.5
Sulfasalazine	56	4.4	4.4
Olaparib	15	4.3	4.3
Sumatriptan Succinate	18	4.3	4.3
Bendamustine Hcl	11	4.3	4.3
Methotrexate Sodium	316	4.2	4.2
Progesterone	15	4.0	4.0
Sorafenib	13	3.8	3.8
Tofacitinib Citrate	8	3.7	3.7
Everolimus Tablets	10	3.6	3.6
Loperamide Hydrochloride Oral	6	3.5	3.5
Etonogestrel And Ethinyl Estradiol	13	3.5	3.5
Peginterferon Alfa-2A	31	3.5	3.5
Ustekinumab	56	3.3	3.3
Adalimumab	360	3.3	3.3
Certolizumab Pegol	63	3.3	3.3
Naproxen Sodium Tablet, Coated	7	3.1	3.1
Naproxen Sodium, Coated Tablets	7	3.1	3.1
Naproxen Sodium 220Mg	7	3.1	3.1
Ipilimumab	22	3.1	3.1
Ribavirin	31	2.9	2.9
Drospirenone And Ethinyl Estradiol	21	2.9	2.9
Imatinib Mesylate	13	2.8	2.8
Rasagiline Mesylate	5	2.7	2.7
Teduglutide	6	2.7	2.7
Elvitegravir, Cobicistat, Emtricitabine, And Tenofovir Disoproxil Fumarate	4	2.7	2.7
Secukinumab	57	2.1	2.1
Golimumab	30	2.1	2.1
Alpelisib	3	2.1	2.1
Dupilumab	148	1.9	1.9
Remdesivir	4	1.8	1.8
Dasatinib	11	1.8	1.8
Bictegravir Sodium, Emtricitabine, And Tenofovir Alafenamide Fumarate	5	1.7	1.7
Ledipasvir And Sofosbuvir	5	1.6	1.6
Alirocumab	6	1.4	1.4
Esketamine Hydrochloride	3	1.0	1.0
Guselkumab	6	1.0	1.0
Etonogestrel	8	1.0	1.0
Levonorgestrel	32	1.0	1.0

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.